These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 3791725)

  • 1. Preventing diversification of malignant tumor cells during therapy.
    Nicolson GL; Lotan R
    Clin Exp Metastasis; 1986; 4(4):231-5. PubMed ID: 3791725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenesis of metastatic disease: implications for current therapy and for the development of new therapeutic strategies.
    Poste G
    Cancer Treat Rep; 1986 Jan; 70(1):183-99. PubMed ID: 3510734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can anticancer therapy be improved by sequential use of cytotoxic and cytostatic (differentiating or immunomodulating) agents to suppress tumor cell phenotypic diversification?
    Lotan R; Nicolson GL
    Biochem Pharmacol; 1988 Jan; 37(2):149-54. PubMed ID: 3277636
    [No Abstract]   [Full Text] [Related]  

  • 4. Growth inhibitors in the treatment of malignant neoplasms.
    Kaiser HE; Krenn M; Bodey B; Bodey B
    In Vivo; 2000; 14(1):287-96. PubMed ID: 10757088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of phenotypic diversity and progression in metastatic tumor cells.
    Nicolson GL
    Cancer Metastasis Rev; 1984; 3(1):25-42. PubMed ID: 6370418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug resistance and behavioural phenotype of cancer cells.
    Bashir I; Sikora K; Foster CS
    Cell Biol Int; 1993 Oct; 17(10):907-17. PubMed ID: 8287021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor cell instability, diversification, and progression to the metastatic phenotype: from oncogene to oncofetal expression.
    Nicolson GL
    Cancer Res; 1987 Mar; 47(6):1473-87. PubMed ID: 3545445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Pathways: Targeting Cancer Stem Cells Awakened by Chemotherapy to Abrogate Tumor Repopulation.
    Chan KS
    Clin Cancer Res; 2016 Feb; 22(4):802-6. PubMed ID: 26671994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastasis-Associated genes and metastatic tumor progression.
    Nicolson GL; Moustafa AS
    In Vivo; 1998; 12(6):579-88. PubMed ID: 9891220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gap junctions as targets for cancer chemoprevention and chemotherapy.
    Trosko JE; Ruch RJ
    Curr Drug Targets; 2002 Dec; 3(6):465-82. PubMed ID: 12448698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for recruitment and synchronization in leukemia and solid tumors.
    Mauer AM; Murphy SB; Hayes FA
    Cancer Treat Rep; 1976 Dec; 60(12):1841-4. PubMed ID: 1026338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents.
    Rowinsky EK
    Drugs; 2000; 60 Suppl 1():1-14; discussion 41-2. PubMed ID: 11129167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly administration of paclitaxel: theoretical and clinical basis.
    Marchetti P; Urien S; Cappellini GA; Ronzino G; Ficorella C
    Crit Rev Oncol Hematol; 2002 Dec; 44 Suppl():S3-13. PubMed ID: 12505595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the genesis and regulation of cellular heterogeneity in malignant tumors.
    Poste G; Greig R
    Invasion Metastasis; 1982; 2(3):137-76. PubMed ID: 6765249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Keynote address: integration of cytostatic agents and radiation therapy: a different approach to "proliferating" human tumors.
    Kinsella TJ; Gould MN; Mulcahy RT; Ritter MA; Fowler JF
    Int J Radiat Oncol Biol Phys; 1991 Feb; 20(2):295-302. PubMed ID: 1991691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving concepts in the systemic drug therapy of breast cancer.
    Norton L
    Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-3-S10-10. PubMed ID: 9275000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mechanisms of immune system contribution to efficiency of antitumor cytostatic therapy].
    Stakheeva MN; Kzhyshkowska YG; Buldakov MA; Cherdyntseva NV
    Vopr Onkol; 2015; 61(4):546-55. PubMed ID: 26571821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the MTD paradigm and optimal control for multi-drug cancer chemotherapy.
    Ledzewicz U; Schättler H; Gahrooi MR; Dehkordi SM
    Math Biosci Eng; 2013 Jun; 10(3):803-19. PubMed ID: 24063059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment duration with immune-based therapies in Cancer: an enigma.
    Bantia S; Choradia N
    J Immunother Cancer; 2018 Dec; 6(1):143. PubMed ID: 30518409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormones, vitamins, and growth factors in cancer treatment and prevention. A critical appraisal.
    Lupulescu AP
    Cancer; 1996 Dec; 78(11):2264-80. PubMed ID: 8940995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.